Gracell Biotechnologies
亘喜生物
Executive Summary
Gracell Biotechnologies was a Shanghai/Suzhou-based CAR-T cell therapy company that was acquired by AbbVie for $1.2B in January 2024. The company specialized in dual-target BCMA/CD19 CAR-T therapies and has been delisted from Nasdaq following the acquisition. As Gracell is now a wholly-owned subsidiary of AbbVie, it is no longer available for independent partnerships and presents clear BIOSECURE risk mitigation through US ownership.
Structure: Following AbbVie's $1.2B acquisition, Gracell is now a wholly-owned subsidiary of the US pharmaceutical giant and has been delisted from Nasdaq. The company's pre-acquisition structure likely involved typical VIE arrangements for a Chinese biotech with US listing, but these structural considerations are now moot given full AbbVie ownership.
Ownership & Shareholder Structure
Gracell Biotechnologies → AbbVie
AbbVie acquired Gracell for $1.2B (Jan 2024) for BCMA/CD19 dual CAR-T platform.
Corporate Events
AbbVie acquires Gracell for $1.2B
AbbVie acquired Gracell Biotechnologies for $1.2B to gain its CAR-T cell therapy platform including BCMA/CD19 dual-target CAR-T. Gracell delisted from Nasdaq.
Clinical Trials(34 total)
9
Phase 1
9
EARLY_Phase 1
2
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07249879 | GC511B CAR-T Cell Injection | Ph.1 | NOT YET RECRUITING | 55 |
| NCT07250269 | GC012F Injection | Ph.1 | RECRUITING | 9 |
| NCT07086404 | GC012F Injection infusion | EARLY_Ph.1 | RECRUITING | 12 |
| NCT07072884 | GC012F injection | EARLY_Ph.1 | NOT YET RECRUITING | 15 |
| NCT07058298 | GC012F injection | EARLY_Ph.1 | RECRUITING | 6 |
| NCT06880354 | CLL1 and CD38 Dual-Target CAR-T Cell Injection | Ph.1 | RECRUITING | 37 |
| NCT06759948 | GC012F injection | Ph.1 | NOT YET RECRUITING | 18 |
| NCT06419166 | GC012F injection | EARLY_Ph.1 | WITHDRAWN | 0 |
| NCT06530849 | GC012F Injection | Ph.1 | RECRUITING | 18 |
| NCT06235229 | GC012F | Ph.1, Ph.2 | RECRUITING | 110 |
| NCT06353152 | Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection | Ph.1 | RECRUITING | 12 |
| NCT06110208 | CLL1 and CD38 dual-target CAR-T injection | EARLY_Ph.1 | TERMINATED | 3 |
| NCT05846347 | GC012F injection | Ph.1 | UNKNOWN | 15 |
| NCT05858684 | GC012F injection | EARLY_Ph.1 | UNKNOWN | 18 |
| NCT05840107 | GC012F injection | EARLY_Ph.1 | UNKNOWN | 18 |
| NCT05412329 | GC012F injection | Ph.1 | UNKNOWN | 9 |
| NCT04617704 | GC012F injection | EARLY_Ph.1 | UNKNOWN | 15 |
| NCT05105867 | Anti-CD19 Universal CAR-T Cells injection | EARLY_Ph.1 | UNKNOWN | 15 |
| NCT04935580 | GC012F injection | Ph.1, Ph.2 | UNKNOWN | 20 |
| NCT04595162 | GC019F | Ph.1 | NOT YET RECRUITING | 12 |
Showing 20 of 34 trials
BIOSECURE Risk
Company is now fully owned by US-based AbbVie following the $1.2B acquisition, effectively eliminating BIOSECURE concerns
Key Exposures:
- •Chinese operational assets
- •Local manufacturing capabilities
- •China-based R&D operations
Mitigation: Fully mitigated through AbbVie acquisition - now operates as subsidiary of US pharmaceutical company
BD Intelligence
Therapeutic Areas:
Recent Deals: Company was fully acquired by AbbVie for $1.2B in January 2024, indicating strong validation of CAR-T platform value
Approach: No longer available for independent partnerships - now part of AbbVie. Any engagement would need to go through AbbVie's BD organization.
Red Flags
- ⚠Company no longer independently available for partnerships
- ⚠Limited visibility into post-acquisition integration status
- ⚠Lack of current key personnel information
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 1
- Gov-Connected
- 0
- Clinical Trials
- 34
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (34 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.